KRAS and BRAF mutations in patients with rectal cancer treated with preoperative chemoradiotherapy.

[1]  Linda Mol,et al.  Chemotherapy, bevacizumab, and cetuximab in metastatic colorectal cancer. , 2009, The New England journal of medicine.

[2]  E. Van Cutsem,et al.  Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. , 2009, The New England journal of medicine.

[3]  B. De Moor,et al.  Molecular response to cetuximab and efficacy of preoperative cetuximab-based chemoradiation in rectal cancer. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  A. Grann,et al.  Molecular genetic changes associated with colorectal carcinogenesis are not prognostic for tumor regression following preoperative chemoradiation of rectal carcinoma. , 2009, International journal of radiation oncology, biology, physics.

[5]  P. Castagnola,et al.  Gene expression deregulation by KRAS G12D and G12V in a BRAF V600E context , 2008, Molecular Cancer.

[6]  L. Mazzucchelli,et al.  Wild-type BRAF is required for response to panitumumab or cetuximab in metastatic colorectal cancer. , 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[7]  H. Lenz,et al.  Polymorphisms in Cyclooxygenase-2 and Epidermal Growth Factor Receptor Are Associated with Progression-Free Survival Independent of K-ras in Metastatic Colorectal Cancer Patients Treated with Single-Agent Cetuximab , 2008, Clinical Cancer Research.

[8]  Dongsheng Tu,et al.  K-ras mutations and benefit from cetuximab in advanced colorectal cancer. , 2008, The New England journal of medicine.

[9]  Y. S. Kim,et al.  Individual tumorigenesis pathways of sporadic colorectal adenocarcinomas are associated with the biological behavior of tumors , 2008, Cancer science.

[10]  Robert A. Weinberg,et al.  Ras oncogenes: split personalities , 2008, Nature Reviews Molecular Cell Biology.

[11]  C. Rödel,et al.  Integration of Novel Agents into Combined-Modality Treatment for Rectal Cancer Patients , 2007, Strahlentherapie und Onkologie.

[12]  Sarah Edkins,et al.  Recurrent KRAS codon 146 mutations in human colorectal cancer , 2006, Cancer biology & therapy.

[13]  Rainer Fietkau,et al.  Prognostic significance of tumor regression after preoperative chemoradiotherapy for rectal cancer. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  R. Simon,et al.  Effectiveness of gene expression profiling for response prediction of rectal adenocarcinomas to preoperative chemoradiotherapy. , 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  Rainer Fietkau,et al.  Preoperative versus postoperative chemoradiotherapy for rectal cancer. , 2004, The New England journal of medicine.

[16]  D. Barford,et al.  Mechanism of Activation of the RAF-ERK Signaling Pathway by Oncogenic Mutations of B-RAF , 2004, Cell.

[17]  K. Fransén,et al.  Mutation analysis of the BRAF, ARAF and RAF-1 genes in human colorectal adenocarcinomas. , 2003, Carcinogenesis.

[18]  D. Schaid,et al.  BRAF mutations in colon cancer are not likely attributable to defective DNA mismatch repair. , 2003, Cancer research.

[19]  W. Hohenberger,et al.  Phase I/II trial of capecitabine, oxaliplatin, and radiation for rectal cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[20]  M. Stratton,et al.  Similarity of the phenotypic patterns associated with BRAF and KRAS mutations in colorectal neoplasia. , 2002, Cancer research.

[21]  G. Capellá,et al.  Codon 12 and codon 13 mutations at the K‐ras gene induce different soft tissue sarcoma types in nude mice , 2002, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[22]  R. Labianca,et al.  Specific codon 13 K-ras mutations are predictive of clinical outcome in colorectal cancer patients, whereas codon 12 K-ras mutations are associated with mucinous histotype. , 2002, Annals of oncology : official journal of the European Society for Medical Oncology.

[23]  K. Kinzler,et al.  Tumorigenesis: RAF/RAS oncogenes and mismatch-repair status , 2002, Nature.

[24]  Theresa M. Grana,et al.  Ras mediates radioresistance through both phosphatidylinositol 3-kinase-dependent and Raf-dependent but mitogen-activated protein kinase/extracellular signal-regulated kinase kinase-independent signaling pathways. , 2002, Cancer research.

[25]  A. Nicholson,et al.  Mutations of the BRAF gene in human cancer , 2002, Nature.

[26]  이석호,et al.  Kirsten ras mutations in patients with colorectal cancer: the ‘RASCAL II’ study , 2001, British Journal of Cancer.

[27]  R. Muschel,et al.  The Ras radiation resistance pathway. , 2001, Cancer research.

[28]  I. Alvarado,et al.  Specific c-K-ras Gene Mutations as a Tumor-Response Marker in Locally Advanced Rectal Cancer Treated With Preoperative Chemoradiotherapy , 2000, Annals of Surgical Oncology.

[29]  G. Capellá,et al.  K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. , 2000, Cancer research.

[30]  A. Bagni,et al.  Usefulness of endorectal ultrasound after preoperative radiotherapy in rectal cancer , 2000, Diseases of the colon and rectum.

[31]  Takashi Tsuruo,et al.  Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors , 1999, Oncogene.

[32]  U. Rapp,et al.  Oncogene activation: c-raf-1 gene mutations in experimental and naturally occurring tumors. , 1993, Toxicology letters.

[33]  G. Cooper,et al.  Relationship among guanine nucleotide exchange, GTP hydrolysis, and transforming potential of mutated ras proteins , 1988, Molecular and cellular biology.

[34]  R. Heald,et al.  RECURRENCE AND SURVIVAL AFTER TOTAL MESORECTAL EXCISION FOR RECTAL CANCER , 1986, The Lancet.

[35]  R. Simon,et al.  Aneuploidy-dependent massive deregulation of the cellular transcriptome and apparent divergence of the Wnt/beta-catenin signaling pathway in human rectal carcinomas. , 2006, Cancer research.